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Abstract
Evidence-based medicine (EBM) is defined as using the best
available evidence for managing patients in daily healthcare prac-
tice. Although this approach has been applied successfully in
many medical fields, it has not been addressed fully in the radio-
logical discipline in general and nuclear medicine in particular.
In this review, the concept of EBM has been introduced briefly
and four steps of EBM practice have been explained. Asking
answerable questions and finding the best evidence that consti-
tutes the first two parts of EBM practice are explained in brief.
The next two steps (appraising the available evidence and ap-
plying the best evidence) are explained in more detail. Since the
bulk of nuclear medicine studies are of a diagnostic nature and
most of the daily practice of a nuclear medicine specialist is in-
volved in diagnosis, we have focused on the diagnosis studies.
Systematic reviews are also explained to some extent. Apprais-
als of other kinds of study, such as interventional or prognosis
studies, are not included in this review.
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Introduction
Evidence based medicine (EBM) is a relatively new approach
to provide health care by which the best evidence is found for
a definite clinical question and is applied in the most efficient
way. Although this kind of practice is becoming the standard in
patient care, it can be very time consuming and the users of this
approach have to be equipped with efficient ways to succeed
[1, 2]. However, application of EBM in radiology and allied dis-
ciplines (such as nuclear medicine) has not been addressed fully
to date [3–6].
In EBM, standard techniques are used for searching the bulk
of literature, and appraising the relevant data (regarding the va-
lidity and effect size). This property makes the results of the EBM
approach reproducible. Reproducibility is the main difference be-
tween traditional and evidence based approaches to medical
practice [2, 7–8]. Usually EBM practice is divided to 4 steps
[7–8], which are shown in Table 1.
In this review these 4 steps are explained with the main focus
on the diagnostic studies which constitute the major part of nucle-
ar medicine practice.
Step 1: asking an answerable question
This step is the cornerstone of EBM practice. Asking an an-
swerable question is defined as taking clinical data and converting
them into a format to be used in the next steps mentioned above
[9].
To achieve this goal, our clinical question has to be divided
into several distinct sections:
1 — the specific group the patient belongs to;
2 — the test we want to apply for the diagnosis of the disease;
Table 1. Four steps of evidence based medicine (EBM) practice
Step I: Asking an answerable question
Step II: Searching for the best evidence
Step III: Critical appraisal of the evidence
Step IV: Applying the evidence to an individual patient
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3 — the test with which we would like to compare the test in part 2
(usually the gold standard);
4 — the intended outcome.
“PICO” is the acronym for this 4-part question: “P” for patient,
“I” for intervention, “C” for comparison and “O” for outcome. This
format for questioning is extremely helpful for searching the avail-
able literature for the best evidence.
The final question is usually expressed in a single sentence.
The major parts of this sentence can be underlined for convenience
in future searches. The following example would be helpful in this
regard.
Assume that you are a Nuclear Medicine specialist, and the
pneumonologist of your hospital wants to know if you can help in
the differentiation between active and inactive tuberculosis in
an adult patient with a history of treated pulmonary tuberculosis
(6 months ago), since the results of the sputum culture take se-
veral weeks to be ready. The pneumonologist has heard about
the application of 99mTc-sestamibi in this clinical situation in
a scientific meeting and wants to know if 99mTc-sestamibi can help
in this regard, or not. The answerable question for this scenario is
shown in Table 2.
As mentioned above, without formulating a PICO question in
every distinct clinical scenario, the other steps of EBM practice
cannot be completed. It is recommended that adequate time be
spent practicing this step [9].
Step 2: searching for the best evidence
In the growing world of internet and computer science, find-
ing the best evidence is becoming increasingly difficult and time
consuming. This is the main obstacle for finding the best evi-
dence in the published medical literature. For example, Ely et
al. reported that family physicians asked an average of 3.2 ques-
tions for every 10 patients seen in an ambulatory clinic, but only
pursued answers to 36% of those questions [10]. In another
study by Ely et al. inadequate time for search is introduced as
one of the main reasons for not using the best evidence in daily
practice [11]. If we want to use the best available evidence, we
should be equipped with a good strategy for searching the lite-
rature.
Medical literature resources
Available medical resources for using in EBM practice are
evolving very rapidly and not all resources are high in quality. It is
recommended that the medical resources be categorized in
a hierarchical manner [12]. Original studies are at the bottom of
this hierarchy, synthetic literature (systematic reviews) are the next
level, the synopses of studies and syntheses are the next, and
finally evidence-based information systems (the most compre-
hensive resource) would be at the top of the hierarchy. This hier-
archy is usually called the “4S” which stands for (from bottom to
top): “studies”, “summaries”, “synopses”, and “systems”. When
seeking the best available evidence, the highest-level resource
available for the problem should be searched first [9, 12].
The evidence based “systems” include all relevant evidence
regarding a clinical problem and are updated on a regular basis to
provide the most up to date available evidence. These systems
are usually under strict review process. Two of these “systems”
are UpToDate (http://www.uptodate.com) and Clinical Evidence
(http://www.clinicalevidence.com). They are not freely available
online; however, those physicians who have University Athens sys-
tem subscription can have access to them.
“Synopses” are the next level of medical resources. As the
name implies, these are synopses of original studies and sys-
tematic reviews. Usually these “synopses” provide structured ab-
stracts of studies that meet the preset criteria, in addition to
an accompanying commentary by an expert on the study results.
They are usually peer reviewed extensively as well. The “synop-
ses” can be considered as a shortcut to find an answer to a cli-
nical question. Two examples of this level of resources are Evi-
dence Based Nursing and ACP Journal Club. They are not freely
available on the net either.
Synthetic literature constitutes the next “S” which is “synthe-
ses”. Databases for systematic reviews are in this level. It should
be noted that review articles, although very useful, are the opi-
nions of individuals on a topic and can be very misleading since
there is no standard method for preparing them. By way of con-
trast, systematic reviews and meta-analyses are objective reviews,
which are more reliable than the review articles. The main charac-
teristics of narrative review articles, systematic reviews, and meta-
analyses are depicted in Table 3. The most comprehensive data-
Table 2. Answerable question for a clinical scenario
Patient or problem Adult patient with a history of treated pulmonary tuberculosis
Intervention 99mTc-sestamibi scintigraphy
Comparison Sputum culture
Outcome Differentiation of active from inactive pulmonary tuberculosis
Question In an adult patient with a history of treated pulmonary tuberculosis, how sensitive is 99mTc-sestamibi scintigraphy
for differentiation of active from inactive pulmonary tuberculosis?
Table 3. Characteristics of narrative review articles, systematic reviews, and meta-analyses
Narrative review articles Systematic reviews Meta-analyses
Methods to collect and interpret data Methods to collect and interpret data Quantitative. Otherwise the same
are subjective are objective as systematic review
Not appraisable Appraisable
Replication impossible Easily replicable
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base for systematic reviews is the Cochrane Library (http://
www.cochrane.org). This database has a collection of systemat-
ic reviews prepared according to its own standards and it pro-
vides a list of other systematic reviews in the medical literature. It
is not free but it can be accessed through an Athens system sub-
scription.
Individual “studies” are in the bottom of the medical resources
hierarchy. Searching for the best evidence in this level is time-con-
suming and found articles need to be critically appraised. Many
databases are available for medical literature. Two of the most com-
monly used databases are SCOPUS (http://www.scopus.com) and
Medline’s Pubmed (http://www.ncbi.nlm.nih.gov/pubmed).
Although there are many medical resources which provide the
best available evidence, currently only a few of them address the
issues of radiology and nuclear medicine. For the questions re-
garding interventions and treatment, usually the Cochrane Library
should be searched for any systematic review or RCT. If this search
does not yield any useful article, Pubmed (or other resources) is
recommended. However, when the clinical question is of a diag-
nostic nature (as is the case for the majority parts of Nuclear Medi-
cine practice), Pubmed is recommended, especially the Clinical
Queries option within it [13–14].
A detailed explanation of searching medical databases such
as Pubmed is beyond the scope of this review and can be found
elsewhere in the literature [9, 14].
Full-text articles: how to get them
Many Nuclear Medicine journals are freely available online. The
Iranian Journal of Nuclear Medicine, the Hellenic Journal of Nucle-
ar Medicine, Nuclear Medicine Review, Nuklearmedizin, the Quar-
terly Journal of Nuclear Medicine and Molecular Imaging, the An-
nals of Nuclear Medicine (not the recent issues), the Journal of
Nuclear Medicine (not the recent issues), and the Journal of Nucle-
ar Medicine Technology (not the recent issues) are among such
freely accessible journals. For those physicians who have a univer-
sity Athens system subscription, most of the other journals are also
freely available. This is also true for the Cochrane Library and its
systematic reviews.
Step 3: critical appraisal
Not all published articles are of high quality regarding the level
of evidence. Critical appraisal is the process of evaluating individ-
ual studies to determine the level of evidence, which is an easy
and efficient way to do this task.
Levels of evidence
The Oxford Centre for Evidence Based Medicine provides a
free online table of levels of evidence (Table 4) [15]. With the guide
of these tables, we can assign a level of evidence to each article in
order to select the highest quality studies. By this strategy, there
would be no need to read all articles regarding a clinical question.
Many poor quality articles can be omitted in this step.
For each study, several questions have to be answered in or-
der to assign a level of evidence. Several free appraisal sheets are
available online for this purpose [16, 17]. These sheets contain two
main parts:
1 — questions regarding the validity which can be found in the
materials and methods section.
2 — the effect size or strength of the study, which is presented
in the results section. The first section is the main part to be used
for assigning the level of evidence [18].
Question 1: What was the spectrum of patients
who underwent the test in question?
Whole spectrum of target disease should be covered in the
study considering the severity and temporality (mild and severe
disease, acute and chronic disease). Randomization would ensure
avoiding selection bias. The characteristics of the patients (such
as gender, age, ethnicity, etc) should be considered to assure that
Table 4. Oxford centre for evidence-based medicine levels of evidence for diagnosis studies (reproduced with permission)
Level Diagnosis
1a SR (with homogeneity*) of Level 1 diagnostic studies; CDR† with 1b studies from different clinical centres
1b Validating** cohort study with good†† reference standards; or CDR† tested within one clinical centre; Independent blind comparison
of an appropriate spectrum of consecutive patients, all of whom have undergone both the diagnostic test and the reference standard
1c Absolute SpPins and SnNouts†††
2a SR (with homogeneity*) of level > 2 diagnostic studies
2b Exploratory** cohort study with good†††reference standards; CDR† after derivation, or validated only on split-sample§  or databases;
Independent blind comparison but either in non-consecutive patients or confined to a narrow spectrum of study patients (or both),
all of whom have undergone both the diagnostic test and the reference standard; or a clinical decision rule not validated
3a SR (with homogeneity*) of 3b and better studies
3b Non-consecutive study; or without consistently applied reference standards
4 Case-control study, poor or non-independent reference standard
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles”
By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Not all sys-
tematic reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant. As noted above, studies dis-
playing worrisome heterogeneity should be tagged with a “–” at the end of their designated level. **Validating studies test the quality of a specific diagnostic test, based on prior
evidence. An exploratory study collects information and trawls the data (e.g. using regression analysis) to find which factors are “significant”; † Clinical decision rule. (These are
algorithms or scoring systems which lead to a prognostic estimation or a diagnostic category); †† Good reference standards are independent of the test, and are applied blindly or
objectively, applied to all patients. Poor reference standards are haphazardly applied, but still independent of the test. Use of a non-independent reference standard (where the
test is included in the reference, or where the 'testing' affects the reference) implies a level 4 study; ††† An “Absolute SpPin” is a diagnostic finding, the Specificity of which is so
high that a Positive result rules-in the diagnosis. An “Absolute SnNout” is a diagnostic finding, the Sensitivity of which is so high that a Negative result rules-out the diagnosis; §
Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into “derivation” and “validation” samples
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the study is applicable to the patients on whom the test is going to
be used [16, 19]. The eligibility criteria should also be defined me-
ticulously [19].
A narrow spectrum of recruited patients would place a study in
level 2 of evidence. For example, in a study by Ahmadihosseini et
al., the application of 99mTc-MIBI in pulmonary tuberculosis diagno-
sis was evaluated [20]. A rapid review of the abstract of this article
shows that a narrow spectrum of patients entered the study (only
patients with active or inactive treated tuberculosis). A good spec-
trum of patients in this study would be all patients with respiratory
symptoms that are indicative of tuberculosis.
Question 2: Was the reference standard the best
available test?
The reference standard is the test used in a study to estab-
lish the diagnosis of the studied disease. Special care is needed
to select the best available test for this purpose. Sputum culture
for pulmonary tuberculosis and pulmonary angiography for pul-
monary embolism are two examples in this regard. Sometimes,
follow up instead of reference standard is used to find out if the
patient has the disease or not. In this case, the period of follow
up should be long enough considering the nature of the disease
[16, 19]. In some clinical scenarios, there is no single best refe-
rence standard, and a combination of clinical findings and para-
clinical tests should be used. For example, this strategy should
be used for the diagnosis of recurrent lymphoma lesions [21].
A poor reference standard would place a study in level 4 of evi-
dence.
For example, in a study by Fallahi et al. the value of 99mTc-MIBI
for diagnosis of multiple myeloma lesions was evaluated. The refe-
rence standard in this study was a combination of clinical and para-
clinical tests, which seems to be the best available reference stan-
dard [22].
An example of poor reference standard would be the detec-
tion rate of sentinel lymph node by lymphoscintigraphy instead of
using axillary lymph node dissection (ALND) [23].
Question 3: Were the reference standard
and the index test applied to all patients
in the study regardless of the index test results?
The reference standard test should be used for all patients
(regardless of index test results). The most common flaw in the
diagnosis studies is failure to meet this criteria [18]. This would
place a study in the level 3 of the evidence.
For example, in a study by Kostakoglu et al. [24] on 67Ga diag-
nostic efficacy for diagnosis of active lymphoma in the residual
masses after treatment of lymphoma, the authors obtained a sen-
sitivity of 96% and a specificity of 80%. However, the gold standard
of the study (biopsy) was not performed for all patients. Apparent-
ly, the positive result of 67Ga was the main decision-maker for the
application of biopsy in this study.
The period between reference standard and index test has to
be considered since it should be short enough to assure that the
target disease did not change between the reference standard and
the index test [17]. For example, the time between a pulmonary
embolism event and pulmonary angiography should not be too
long, since the thrombolysis process can interfere in the diagnosis
of pulmonary embolism.
Question 4: Was the comparison between the in-
dex test and reference standard blind and indepen-
dent?
The interpreters of the index and reference standard tests
should be blind to the results of each test in order to avoid expec-
tation bias [19], which can place a study in level 4 of evidence.
Question 5: Were the index test and reference
standard explained fully in the article?
Reliable duplication of the results of each study depends on
this question. For example, the type of collimator, the type of gam-
ma camera, etc. should be mentioned in the study.
The above-mentioned questions are very important to assign
a level of evidence to each article. Many articles (with low validity)
can be omitted at this point and not reviewed further. The remain-
ing questions evaluate the results of the study.
Question 6: What were the results of the study?
For diagnostic tests, sensitivity, specificity, and positive and
negative predictive values (PPV and NPV) should be considered
and can usually be found in the results section of studies. Figure 1
shows a 2 × 2 chart for a dichotomous test. The definitions can be
found in Table 5.
When the results of a test are of multilevel or continuous nature
(such as gated SPECT indices), the cut-off value of the index test is
the main determinant of the sensitivity and specificity. In these sit-
uations, there is a negative correlation between sensitivity and spe-
cificity. This is the basis of receiver operating characteristic (ROC)
analysis. The ROC curve shows the sensitivity and specificity for
different cut-off points of the test results. It is very important to con-
Table 5. Definitions of the characteristics of the test shown
in Figure 1
Characteristic Definition Formula
of the test
Sensitivity How good is this test at detecting a/(a + c)
people with the disease?
Specificity How good is this test at correctly d/(b + d)
excluding people without the disease?
Positive What is the probability that a person a/(a + b)
predictive value with a positive test has the disease?
Negative What is the probability that a person d/(c + d)
predictive value with a negative test
does not have the disease?
Accuracy What proportion of all tests (a + d)/
yielded the correct result? /(a + b + c + d)
Figure 1. 2 × 2 chart for a test with dichotomous results.
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sider the area under the curve in ROC analysis. If this area equals
0.5, the test is of no use. When this area approaches unity, the
performance of the test increases (Figure 2).
Sensitivity and specificity are inherent properties of a test and
are constant no matter what the prevalence of the disease in the
tested population. In contrast, predictive values [both negative (NPV)
and positive (PPV)] are dependent on the prevalence of the disease
in the population. This is the cornerstone of the Bayes’ Theorem,
which is discussed further at the end of this article [5–6, 25].
Question 7: Were the confidence intervals
mentioned for the test results?
In addition to p-values, sensitivity, and specificity, other impor-
tant values should be mentioned for sufficient interpretation. The
P-value is only a probability that an outcome has occurred by
chance. It is definitely not a substitute for effect size. To appreciate
the effect size of a study, the confidence intervals are very useful.
A wide confidence interval range indicates a small sample size [26].
For example, the sensitivity of a test can be 80% in two different
studies; however, the confidence intervals for this sensitivity can
be 70–90% and 40–97%, respectively. The first study provides bet-
ter evidence in this regard. Online calculators are freely available
for confidence interval calculation [27].
A full explanation of this issue is beyond the scope of this
article, but an excellent book written by Cohen addresses this is-
sue in detail [28].
Step 4: applying the evidence to a particular
patient
As mentioned before, the predictive values of a test are de-
pendent on the prevalence of a disease in a society. This preva-
lence is usually called pre-test probability. The post-test probabili-
ty is the refined probability of a disease when both pre-test proba-
bility and test results are considered together. For this purpose,
likelihood ratios (LRs) are used, which are defined in Table 6. For
a given pre-test probability (prevalence), pre-test odds can also
be calculated.
PRE−TEST ODDS = PRE−TEST PROBABILITY/
/(1−PRE−TEST PROBABILITY)
These ratios (odds and likelihood ratios) can be combined to-
gether by multiplication [18]. No matter how many test are used to
refine a probability, this method can be applied as follows:
POST−TEST ODDS = PRE−TEST ODDS ¥ LR of test 1 ¥
¥ LR of test 2 ¥ LR of test 3...
Finally, the post-test probability of the disease can be calcula-
ted from the calculated odds:
POST−TEST PROBABILITY = POST−TEST ODDS/
/(POST−TEST ODDS + 1)
The concept of pre and post-test probability is shown in Figure
2 in another way.
Usually a threshold is set for the probability of each disease for
treatment, above which treatment is justified. For example, this
threshold for malignant bone tumours is very high (the diagnosis
of malignant bone tumours should be almost definite (near 100%)
to justify treatment). This is also the case for pulmonary embolism:
the probability of the presence of pulmonary embolism should be
more than 80% (high probability) to begin treatment.
The main application of a para-clinical test is refining the pre-
test probability for a particular patient. If the post-test probability
becomes higher than the treatment threshold, the treatment of the
disease is justified and vice versa (Figure 3).
Other important issues to be addressed
For implementing the best found evidence in every day prac-
tice, cultural and religious issues should be considered. Some tests
and procedures may not be culturally acceptable (no matter how
good the performance is), and before requesting a test this impor-
tant fact should be born in mind.
Table 6. The definitions of likelihood ratios (LRs) for the test
shown in Table 1
Characteristic Definition Formula
of the test
Likelihood What is the likelihood of a positive sensitivity/
ratio test result being found /(l-specificity)
of a positive test for a person with the disease
compared to a person without it?
Likelihood What is the likelihood of a negative (l-sensitivity)/
ratio test being found for a person /specificityof
a negative test without the disease compared
to a person with it?
Figure 2. Receiver operating characteristic (ROC) curves of three differ-
ent tests. Larger area under the curve for each test (location of the curve
to the left and top) indicates better performance. For example the test
“c” performs best, and test “a” performs worst.
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Economical issues are another important aspect to be consid-
ered. With limited budget for health care, many expensive proce-
dures and tests should not be ordered. This is beyond the scope
of this review, but you can find a more detailed explanation else-
where in the literature [29].
References
1. Wood BP. What’s the evidence? Radiology 1999; 213: 635–637.
2. Evidence-Based Radiology Working Group. Evidence-based radiolo-
gy: a new approach to the practice of radiology. Radiology 2001; 220:
566––575.
3. van Beek EJ, Malone DE. Evidence-based practice in radiology educa-
tion: why and how should we teach it? Radiology 2007; 243: 633–640.
4. Del Mar C, Glasziou P, Mayer D. Teaching evidence based medicine
[editorial]. BMJ 2004; 329: 989–990.
5. Alvarez Ruiz S, Cortés Hernández J, Rodeno Ortiz De Zárate E, Alon-
so Colmenares JI, Alcorta Armentia P. Evidence based medicine. Gen-
eralizations on the application to nuclear medicine. Part I. Rev Esp
Med Nucl 2001; 20: 313–328.
6. Alvarez Ruiz S, Canut Blasco A, Rodeno Ortiz de Zárate E et al. Evi-
dence based medicine. Application to nuclear medicine. Diagnostic
slope. Part II. Rev Esp Med Nucl 2001; 20: 393–412.
7. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS.
Evidence based medicine: what it is and what it isn’t. BMJ 1996; 312:
71–72.
8. Introduction. In: Sackett DL, Strauss SE, Richardson WS, Rosenberg
W, Haynes RB. Evidence based medicine: how to practice and teach
EBM. 2nd ed. Churchill Livingstone, Edinburgh 2000; 1–12.
9. Staunton M. Evidence-based radiology: steps 1 and 2 — asking an-
swerable questions and searching for evidence. Radiology 2007; 242:
23–31.
10. Ely JW, Osheroff JA, Ebell MH et al. Analysis of questions asked by
family doctors regarding patient care. BMJ 1999; 319: 358–361.
11. Ely JW, Osheroff J, Ebel M et al. Obstacles to answering doctors’ ques-
tions about patient care with evidence: qualitative study. BMJ 2002; 2:
265–268.
12. Haynes RB. Of studies, summaries, synopses, and systems: the “4S”
evolution of services for finding current best evidence. Evid Based Nurs
2005; 8: 4–6.
13. The Cochrane Library Help. http://www3.interscience.wiley.com/cgi-
bin/mrwhome/106568753/cochranedemo.ppt. Accessed April 5, 2009.
14. Greenhalgh T. How to read a paper. The Medline database. BMJ 1997;
315: 180–183.
15. Levels of evidence. Oxford Centre for Evidence-Based Medicine Web
site. http://www.cebm.net/index.aspx?o=1025.Accessed April 12,
2009.
16. Diagnostic Critical Appraisal Sheet. Oxford Centre for Evidence-Based
Medicine Web site. http://www.cebm.net/index.aspx?o=1096.
Accessed April 13, 2009.
17. Scottish Intercollegiate Guidelines Network (SIGN) Web site. http://
www.sign.ac.uk/methodology/checklists.html. Accessed April 12, 2009.
18. Dodd JD. Evidence-based practice in radiology: Steps 3 and 4
Appraise and apply diagnostic radiology literature. Radiology 2007;
242: 342–354.
19. Greenhalgh T. How to read a paper. Papers that report diagnostic or
screening tests. BMJ 1997; 315: 540–543.
20. Ahmadihosseini H, Sadeghi R, Zakavi R, Dabbagh Kakhki VR, Haghighi
Kakhki AR. Application of Technetium-99m-sestamibi in differentiation
of active from inactive pulmonary tuberculosis using SPECT method.
Nucl Med Commun 2008; 29: 690–694.
21. Hoda S. Role of nuclear medicine in detection and management of
Hodgkin’s disease and non-Hodgkin’s lymphoma. Iran J Nucl Med
2002; 16-17: 17–25.
22. Fallahi B, Saghari M, Fard A et al. The value of 99mTc-MIBI whole
body scintigraphy in active and in remission multiple myeloma. Hell J
Nucl Med 2005; 8: 165–168.
23. Heuts E. Excision biopsy of breast lesions changes the pattern of lym-
phatic drainage. Br J Surg 2007; 94: 1573.
24. Kostakoglu L, Yeh SDJ, Portlock C et al. Validation of Gallium-68-cit-
rate single-photon emission computed tomography in biopsy-confirmed
residual Hodgkin's disease in the mediastinum. J Nucl Med 1992; 33:
345–350.
25. Diagnosis and screening. In: Sackett DL, Strauss SE, Richardson WS,
Rosenberg W, Haynes RB. Evidence based medicine: how to practice
and teach EBM. 2nd ed. Churchill Livingstone, Edinburgh 2000; 1–12.
26. Greenhalgh T. How to read a paper. Statistics for the non-statistician II:
"Significant" relations and their pitfalls. BMJ 1997; 315: 422–425.
27. CAT maker software. Oxford Centre for Evidence-Based Medicine Web
site. http://www.cebm.net/index.aspx?o=1216.Accessed April 13,
2009.
28. Cohen J. Statistical power analysis for the behavioral sciences. 2nd
ed. Lawrence Erlbaum Associates, 1988.
29. Greenhalgh T. How to read a paper. Papers that tell you what things
cost (economic analyses). BMJ 1997; 315: 596–599.
Figure 3. Graph showing the correlation between pre-test probability
and both negative and positive results of a particular test. For a patient
with a pre-defined pre-test probability (vertical arrow), the post-test pro-
bability after getting positive and negative results (A and B, respectively)
would be those shown by horizontal arrows. The treatment threshold is
shown by a white arrow (C). Since B > C, a positive result of this parti-
cular test would justify treatment. In contrast, A < C so a negative result
of this test would not justify treatment.
